Question: There’s buzz around the office of a respiratory syncytial virus (RSV) vaccine. Is it available yet? If so, how do we code it? Maryland Subscriber Answer: Yes, there is a vaccine, and it is available now. The FDA announced on May 3, 2023, that Arexvy is approved for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.
For reporting and reimbursement purposes, the American Medical Association (AMA) released a new CPT® code for the vaccine, which is 90679 (Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use). Be sure to report this with the appropriate administration code, such as 90471 (Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)). Note: Although the new product code was effective May 3, 2023, check with payers to make sure they’re able to process claims for the new vaccine.